The leading market experts have placed a mean price target of $140.83 on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock. This price level, which is estimated to be attained in one-year, indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $1.26 a share for the upcoming quarter and $3.45 for the current fiscal.
The technical analysis of Ligand Pharmaceuticals Incorpor plainly substantiates that the 50-day moving average of Ligand Pharmaceuticals Incorpor is $125.68, and stock is trading $-11.74 points away or -9.34% from its 50-day moving average of $125.68. Further it is trading $0.43 or +0.38% away its 200-day moving average of $113.51. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) 52-week high is $139.79 and the 52-week low is $71.63.
This explains if the stock moves $-25.85, it will post a 52-week high. In event of +59.07% decline, a 52-week low will be hit.
Taking the valuation aspect to emphasize the valuation of Ligand Pharmaceuticals Incorpor, shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ratio came in at 10.74.
The stock last ended the trading session at $113.94 and registered a market cap of $2.38B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PEG ratio is at 0.72.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...